Look­ing at a ground­break­ing ad­vance, My­ovant gets a pri­or­i­ty re­view at FDA; Agenus, G1 forge new Chi­na deals

→ Just weeks af­ter post­ing promis­ing piv­otal re­sults for re­l­u­golix in prostate can­cer, My­ovant has picked up a pri­or­i­ty re­view from the FDA, which isn’t plan­ning an ex­pert com­mit­tee re­view be­fore mak­ing its de­ci­sion. While much of the at­ten­tion in this class is fo­cused on uter­ine fi­broids, an OK here would make this the first GnRH re­cep­tor an­tag­o­nist treat­ment for men with ad­vanced prostate can­cer.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.